Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response

Authors: Wei-Jing Gong, Ji-Ye Yin, Xiang-Ping Li, Chao Fang, Di Xiao, Wei Zhang, Hong-Hao Zhou, Xi Li, Zhao-Qian Liu

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) play important roles in carcinogenesis and drug efficacy. Platinum-based chemotherapy is first-line treatment for lung cancer chemotherapy. In this study, we aimed to investigate the association of well-characterized lung cancer lncRNA genetic polymorphisms with the lung cancer susceptibility and platinum-based chemotherapy response. A total of 498 lung cancer patients and 213 healthy controls were recruited in the study. Among them, 467 patients received at least two cycles of platinum-based chemotherapy. Thirteen polymorphisms in HOXA distal transcript antisense RNA (HOTTIP), HOX transcript antisense intergenic RNA (HOTAIR), H19, CDKN2B antisense RNA 1 (ANRIL), colon cancer-associated transcript 2 (CCAT2), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and maternally expressed gene 3 (MEG3) genes were genotyped by allele-specific MALDI-TOF mass spectrometry. We found that patients with HOTTIP rs5883064 C allele or rs1859168 A allele had increased lung cancer risk (P = 0.01, P = 0.01, respectively). CCAT2 rs6983267 (P = 0.02, adenocarcinoma) and H19 rs2107425 (P = 0.02, age under 50 years) showed strong relationship with lung cancer susceptibility. CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively). ANRIL rs10120688 (P = 0.02, adenocarcinoma) and rs1333049 (P = 0.04, small-cell lung cancer), H19 rs2107425 (P = 0.02, small-cell lung cancer) and HOTAIR rs1899663 (P = 0.03, male; P = 0.03, smoker) were associated with response to platinum-based chemotherapy. HOTTIP, CCAT2, H19, HOTAIR, MALATI, ANRIL genetic polymorphisms were significantly associated with lung cancer susceptibility or platinum-based chemotherapy response. They may be potential clinical biomarkers to predict lung cancer risk and platinum-based chemotherapy response.
Appendix
Available only for authorised users
Literature
1.
Parkin D, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:594–606.CrossRefPubMed
2.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
3.
4.
5.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629–41.CrossRefPubMed
6.
7.
Okazaki Y, Furuno M, Kasukawa T, Adachi J, Bono H, Kondo S, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature. 2002;420:563–73.CrossRefPubMed
8.
Li XP, Yin JY, Wang Y, He H, Li X, Gong WJ, et al. The atp7b genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumor Biol. 2014;35:8259–65.CrossRef
9.
Yin JY, Huang Q, Yang Y, Zhang JT, Zhong MZ, Zhou HH, et al. Characterization and analyses of multidrug resistance-associated protein 1 (mrp1/abcc1) polymorphisms in Chinese population. Pharmacogenet Genomics. 2009;19:206.CrossRefPubMedPubMedCentral
10.
Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci. 2009;106:9362–7.CrossRefPubMedPubMedCentral
11.
Liu Y, Pan S, Liu L, Zhai X, Liu J, Wen J, et al. A genetic variant in long non-coding rna hulc contributes to risk of hbv-related hepatocellular carcinoma in a Chinese population. PLoS One. 2012;7:e35145.CrossRefPubMedPubMedCentral
12.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMed
13.
Deng H, Chen L, Fan T, Zhang B, Xu Y, Geng Q. Long non-coding RNA hottip promotes tumor growth and inhibits cell apoptosis in lung cancer. Cell Mol Biol (Noisy-le-Grand France). 2014;61:34–40.
14.
JiP D, Wang W. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031.CrossRef
15.
Schmidt LH, Spieker T, Koschmieder S, Humberg J, Jungen D, Bulk E, et al. The long noncoding malat-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6:1984–92.CrossRefPubMed
16.
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, et al. Long non-coding RNA malat-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2012;29:1810–6.CrossRefPubMed
17.
Gabory A, Jammes H, Dandolo L. The h19 locus: role of an imprinted non-coding RNA in growth and development. Bioessays. 2010;32:473–80.CrossRefPubMed
18.
Kondo M, Suzuki H, Ueda R, Osada H, Takagi K, Takahashi T. Frequent loss of imprinting of the h19 gene is often associated with its overexpression in human lung cancers. Oncogene. 1995;10:1193–8.PubMed
19.
Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-myc oncogene directly induces the h19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res. 2006;66:5330–7.CrossRefPubMed
20.
Tsang W, Kwok T. Riboregulator h19 induction of mdr1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007;26:4877–81.CrossRefPubMed
21.
Verhaegh GW, Verkleij L, Vermeulen SH, den Heijer M, Witjes JA, Kiemeney LA. Polymorphisms in the h19 gene and the risk of bladder cancer. Eur Urol. 2008;54:1118–26.CrossRefPubMed
22.
Riaz M, Berns EM, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, et al. Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Res Treat. 2012;133:843–51.CrossRefPubMed
23.
Yang C, Tang R, Ma X, Wang Y, Luo D, Xu Z, Zhu Y, Yang L. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. Oncotarget 2015.
24.
Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, et al. Ccat2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23:1446–61.CrossRefPubMedPubMedCentral
25.
Qiu M, Xu Y, Yang X, Wang J, Hu J, Xu L, et al. Ccat2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumor Biol. 2014;35:5375–80.CrossRef
26.
Nakagawa T, Endo H, Yokoyama M, Abe J, Tamai K, Tanaka N, et al. Large noncoding RNA hotair enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochem Biophys Res Commun. 2013;436:319–24.CrossRefPubMed
27.
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W, et al. The long noncoding RNA hotair contributes to cisplatin resistance of human lung adenocarcinoma cells via downregulation of p21 (waf1/cip1) expression. PLoS One. 2013;8:e77293.CrossRefPubMedPubMedCentral
28.
Xue Y, Gu D, Ma G, Zhu L, Hua Q, Chu H, et al. Genetic variants in lncrna hotair are associated with risk of colorectal cancer. Mutagenesis. 2015;30:303–10.CrossRefPubMed
29.
Guo W, Dong Z, Bai Y, Guo Y, Shen S, Kuang G, et al. Associations between polymorphisms of hotair and risk of gastric cardia adenocarcinoma in a population of North China. Tumor Biol. 2015;36:2845–54.CrossRef
30.
Nie FQ, Sun M, Yang JS, Xie M, Xu TP, Xia R, et al. Long noncoding RNA ANRIL promotes non–small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and P21 expression. Mol Cancer Ther. 2015;14:268–77.CrossRefPubMed
31.
Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone h3 lysine 27 by polycomb cbx7 in transcriptional silencing of ink4a. Mol Cell. 2010;38:662–74.CrossRefPubMedPubMedCentral
32.
Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451:202–6.CrossRefPubMedPubMedCentral
33.
Yuan XW, Zhu XF, Huang XF, Sheng PY, He AS, Yang ZB, et al. P14arf sensitizes human osteosarcoma cells to cisplatin-induced apoptosis in a p53-independent manner. Cancer Biol Ther. 2007;6:1074–80.CrossRefPubMed
34.
Deng X, Kim M, Vandier D, Jung YJ, Rikiyama T, Sgagias MK, et al. Recombinant adenovirus-mediated p14 arf overexpression sensitizes human breast cancer cells to cisplatin. Biochem Biophys Res Commun. 2002;296:792–8.CrossRefPubMed
35.
Al-Mohanna MA, Manogaran PS, Al-Mukhalafi Z, Al-Hussein KA, Aboussekhra A. The tumor suppressor p16ink4a gene is a regulator of apoptosis induced by ultraviolet light and cisplatin. Oncogene. 2004;23:201–12.CrossRefPubMed
Metadata
Title
Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response
Authors
Wei-Jing Gong
Ji-Ye Yin
Xiang-Ping Li
Chao Fang
Di Xiao
Wei Zhang
Hong-Hao Zhou
Xi Li
Zhao-Qian Liu
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4497-5

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma

Original Article

Solanum tuberosum lectin inhibits Ehrlich ascites carcinoma cells growth by inducing apoptosis and G2/M cell cycle arrest

Original Article

Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment

Research Article

Predictive factors for recurrence of differentiated thyroid cancer in patients under 21 years of age and a meta-analysis of the current literature

Original Article

ABCE1 plays an essential role in lung cancer progression and metastasis

Original Article

Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits